anacetrapib

From Aaushi
Jump to navigation Jump to search

Introduction

Experimental agent. Drug in phase 1 trials.

Indications

Dosage

Mechanism of action

Clinical trials

Notes

  • Merck announced it will not seek regulatory approval for anacetrapib after disappointing trial results[4]

More general terms

References

  1. Krishna R et al, Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phast I studies. Lancet 2007, 370:1907 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18068514
  2. Physician' First Watch, Nov 18, 2010 Massachusetts Medical Society http://www.jwatch.org
    Cannon CP et al Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease N Engl J Med November 17, 2010 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21082868 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1009744
  3. 3.0 3.1 The HPS3/TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017 Aug 29; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28847206 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1706444
  4. 4.0 4.1 Wendling P Merck Abandons Plans to Pursue Anacetrapib Medscape - Oct 12, 2017. https://www.medscape.com/viewarticle/886953